NCT00259818View on ClinicalTrials.gov

Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2005

Study Completion Date

January 31, 2008

Conditions
Cancer
Interventions
DRUG

EM-1421

Trial Locations (3)

Unknown

Premiere Oncology of Arizona, Scottsdale

Albert Einstein College of Medicine, The Bronx

Sarah Cannon Cancer Center, Nashville

Sponsors
All Listed Sponsors
lead

Erimos Pharmaceuticals

INDUSTRY

NCT00259818 - Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter